Ke Ding

USPTO Granted Patents = 14 (Patent Applications = 11)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 6 (Patent Applications = 13)

Average Co-Inventor Count = 6.7

ph-index = 3

Forward Citations = 87(Granted Patents)

Location History:

Guangzhou, CN (2010 - 2019)
Guangdong, CN (2014 - 2023)

Company Filing History:

8 out of 3,101

Chinese Academy of Sciences

patents

4 out of 3,384

University of Michigan

patents

1 out of 1

Guangzhou Eggbio Co., Ltd.

patent

4. 1 out of 251

Auckland Uniservices Limited

patents

5. 1 out of 2

Guangzhou Institute of Biomedicine and Health

patents

6. 1 out of 5,469

The University of Texas System

patents

7. 1 out of 9

Shanghai Haihe Pharmaceutical Co., Ltd.

Shenzhen Newdel Biotech Co., Ltd.

patent

10. 1 out of 219

Saint Louis University

patents

where one patent can have more than one assignee

Years Active: 2010-2023

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11834454 - Alkynylphenylbenzamide compounds and applications thereof (2023-12-05),

2. 11192890 - FGFR kinase inhibitors and pharmaceutical uses (2021-12-07),

3. 10683278 - Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof (2020-06-16),

4. 10370360 - Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof (2019-08-06),

5. 10155756 - Pyrazolo[1,5-A]pyridine compounds and use thereof (2018-12-18),

6. 10059694 - 2-aminopyrimidine compound and pharmaceutical composition and use thereof (2018-08-28),

7. 9452220 - Coupling compounds of NSAID anti-inflammatory and analgesic drugs and EGFR kinase inhibitors, synthesis methods and applications thereof (2016-09-27),

8. 9353089 - Compositions and methods for the treatment of malaria (2016-05-31),

9. 8901117 - Small molecule inhibitors of MDM2 and the uses thereof (2014-12-02),

10. 8853221 - Compounds of estrogen-related receptor modulators and the uses thereof (2014-10-07),

11. 8846671 - Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof (2014-09-30),

12. 8742121 - Process for the preparation of small molecule inhibitors of MDM2 and intermediates used therein (2014-06-03),

13. 8088931 - Small molecule inhibitors of MDM2 and the uses thereof (2012-01-03),

14. 7759383 - Small molecule inhibitors of MDM2 and the uses thereof (2010-07-20),

Title: Innovator Spotlight: Ke Ding - Pioneering Developments in Pharmaceutical Innovation

Introduction:

Meet Ke Ding, a visionary inventor from Guangzhou, China, whose groundbreaking work in the field of pharmaceuticals has led to 13 patented inventions. His focus on developing cutting-edge solutions for hyper-proliferative diseases has earned him recognition worldwide.

Latest Patents:

Ke Ding's latest patents include FGFR kinase inhibitors for treating various hyper-proliferative diseases such as retinopathy, psoriasis, and rheumatoid arthritis. Additionally, his work on substituted quinolone derivatives has shown promising results in the prevention and treatment of tumors, particularly as protein kinase inhibitors effective in inhibiting tumor cell proliferation and invasion.

Career Highlights:

Ke Ding has made significant contributions to the field of pharmaceuticals through his work at prestigious institutions such as the Guangzhou Institutes of Biomedicine and Health at the Chinese Academy of Sciences, and the University of Michigan. His expertise and dedication to advancing medical research have led to the development of innovative therapies for a range of challenging diseases.

Collaborations:

Throughout his career, Ke Ding has collaborated with esteemed colleagues such as Zhengchao Tu and Shaomeng Wang. Together, they have worked on pioneering projects that have advanced the understanding and treatment of hyper-proliferative diseases, setting new standards for pharmaceutical innovation.

Conclusion:

In conclusion, Ke Ding stands as a trailblazing inventor in the field of pharmaceutical innovation, with a remarkable portfolio of patented inventions that have the potential to revolutionize medical treatment. His collaborative spirit and relentless pursuit of scientific excellence underscore his commitment to improving global healthcare outcomes.

This text is generated by artificial intelligence and may not be accurate.